Ep. 361 - Kelonia, Kailera, pyschedelics and T cell engagers

The past week has delivered the largest M&A deal ever for a private, venture-backed biopharma, the second-largest follow-on ever for a NASDAQ-traded biotech and what could soon become the largest biotech IPO ever on NASDAQ. On the latest BioCentury This Week , BioCentury’s analysts discuss Eli Lilly's $3.25 billion takeout of in vivo CAR T company Kelonia, the market debut by obesity play Kailera and an upsized follow-on by Revolution on the back of its pancreatic cancer data. The analysts also discuss how autoimmune T cell engagers are diverging from their oncology roots and the potential implications of President Donald Trump’s executive order on psychedelic therapies. BioCentury’s analysts also take time to remember Sofinnova Partners’ Denis Lucquin, father of French biotech. This episode of the BioCentury This Week podcast was brought to you by IQVIA Biotech . View full story: 00:01 - Sponsor Message: IQVIA Biotech 04:20 - Lilly's Kelonia Buy 10:31 - T Cell Engagers 23:07 - Psychedelics Executive Order 35:14 - CBER Director Search 37:37 - Public Markets Roundup 42:14 - Remembering Denis Lucquin To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

You can listen to Ep. 361 - Kelonia, Kailera, pyschedelics and T cell engagers online on Radio and Podcast. Open the player on this page to stream the available audio.

Ep. 361 - Kelonia, Kailera, pyschedelics and T cell engagers is an episode from BioCentury This Week by BioCentury.

This episode is 44:02 long.

This episode was published on Apr 21, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from BioCentury This Week when more episodes are available from the podcast feed.